Pin your most used calculators here by clicking the star in the dropdown.
IMDC (Heng) Risk Score
Clinical Context & Background
The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) or Heng Risk Score is a prognostic model used to stratify patients with metastatic renal cell carcinoma (mRCC) treated with targeted therapy. It helps guide treatment selection (e.g., dual immunotherapy vs. TKI/IO combinations).
Formula Logic
Sum of 6 risk factors (1 point each)Reference Data
| Risk Group | Number of Risk Factors | Median Overall Survival |
|---|---|---|
| Favorable Risk | 0 | 43.2 months |
| Intermediate Risk | 1 - 2 | 22.5 months |
| Poor Risk | ≥ 3 | 7.8 months |
Evidence-based oncology decision support. Verify with clinical guidelines.